Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

NCT06830239 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer Stage III

Interventions

DRUG: Dostarlimab

Sponsor

Universitaire Ziekenhuizen KU Leuven